drugset / Trial / NCT00306384
Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the long-term safety of alogliptin, once daily (QD), following participation in 1 of 7 controlled studies in patients with type 2 diabetes mellitus.
Timeline
- Start
- 2006-03
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alogliptin | Unknown | 12.5 mg | Oral |
| Subject | Alogliptin | Unknown | 25 mg | Oral |